Linezolid Dr. Eberth (Linezolid)

Linezolid binds to the 23S rRNA of the bacterial 50S ribosomal subunit, blocking the formation of the initiation complex required for protein synthesis. This inhibition halts bacterial growth (bacteriostatic) and can be bactericidal at higher concentrations, targeting Gram‑positive organisms including MRSA and VRE.

The dosing regimen for Linezolid Dr. Eberth is determined by the prescribing clinician based on the specific infection, patient characteristics, and local guidelines. Healthcare professionals set the appropriate dose and duration; patients should follow the prescriber’s instructions precisely.

Linezolid should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Limited data are available, and it crosses the placenta. While small amounts are found in breast milk, breastfeeding is generally not recommended unless the benefit to the infant outweighs the risk.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Compared with beta‑lactams or glycopeptides, linezolid offers oral bioavailability comparable to intravenous administration, allowing seamless switch to oral therapy. It is active against many resistant Gram‑positive strains, such as MRSA and VRE, where some alternatives may lack efficacy. However, it lacks activity against Gram‑negative organisms and has a distinct safety profile that requires monitoring.

Linezolid Dr. Eberth tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid exposure to extreme temperatures or humidity.

Linezolid Dr. Eberth is supplied as oral tablets that are taken by mouth with or without food. The tablet can be swallowed whole; crushing or chewing is not required. In clinical settings where oral administration is not feasible, an intravenous formulation of linezolid may be used under medical supervision.

The most serious risks include thrombocytopenia, which can lead to bleeding; peripheral neuropathy, which may become irreversible with prolonged therapy; and serotonin syndrome when combined with serotonergic drugs. Patients should be monitored regularly for blood count changes and neurological symptoms, and any serotonergic agents should be avoided.

Linezolid is contraindicated in patients with known hypersensitivity to linezolid or any component of the formulation. It should also be avoided in individuals taking monoamine oxidase inhibitors, serotonergic agents, or those with a history of severe serotonin syndrome. Caution is advised in patients with significant hepatic or renal impairment, and it is not recommended for use in pregnant or breastfeeding women unless absolutely necessary.